PMID- 29657607
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231112
IS  - 1895-5770 (Print)
IS  - 1897-4317 (Electronic)
IS  - 1895-5770 (Linking)
VI  - 13
IP  - 1
DP  - 2018
TI  - Efficacy and safety of pegylated interferon alpha and ribavirin in patients 
      monoinfected with HCV genotype 4.
PG  - 22-29
LID - 10.5114/pg.2018.74558 [doi]
AB  - INTRODUCTION: Dual therapy (PegIFN and ribavirin) (DT) was the standard of care 
      in patients infected with HCV genotype 4 (HCV-4) until 2014. Nowadays, new 
      treatment options are available including interferon (IFN)-based and other 
      IFN-free regimens. AIM: To assess the efficacy (SVR24) and safety of DT and the 
      selected predictor factors of SVR in HCV-4 infected patients. MATERIAL AND 
      METHODS: One hundred and twelve patients (62 men) of median age 23 years were 
      treated with DT for 48/72 weeks (107/5) in the years 2006-2014. Most of them were 
      treatment naive (80.4%) and with fibrosis F </= 2 (83.1%). To select a subset of 
      independent predictors of SVR Logistic Regression Analysis was applied. RESULTS: 
      SVR24 was achieved in 46/112 (41.1%) patients. The mean viral load was 5.55 
      log(10) IU/ml. Lack of therapy experience increases the odds of achieving SVR (OR 
      = 4.17; 1.04-16.67), whereas more advanced fibrosis and higher baseline viral 
      load tend to decrease the probability of SVR (OR = 0.05; 0.01-0.52 and OR = 0.44; 
      0.17-1.13, respectively). In contrast, the weight loss is associated with higher 
      probability of virological response (OR = 4.31; 1.37-13.60). Two hundred and 
      seventy-nine adverse events (AEs) were reported in 96 individuals. The rates and 
      types of AEs were similar in patients treated with PegIFN-alpha2a/RBV and 
      PegIFN-alpha2b/RBV. Overall, 3 (2.7%) patients discontinued therapy prematurely 
      because of serious AEs. CONCLUSIONS: SVR24 was low. Loss of weight was a new 
      positive predictive factor of SVR found in our study. Most of the AEs were 
      typical of those previously reported for DT.
FAU - Kozielewicz, Dorota
AU  - Kozielewicz D
AD  - Department of Infectious Diseases and Hepatology, Faculty of Medicine, Collegium 
      Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland.
FAU - Grabinska, Anna
AU  - Grabinska A
AD  - Second Department of Infectious Diseases, Voivodship Specialist Hospital, 
      Wroclaw, Poland.
FAU - Madej, Grzegorz
AU  - Madej G
AD  - Second Department of Infectious Diseases, Voivodship Specialist Hospital, 
      Wroclaw, Poland.
FAU - Wietlicka-Piszcz, Magdalena
AU  - Wietlicka-Piszcz M
AD  - Department of Theoretical Foundations of Biomedical Sciences and Medical Computer 
      Science, Faculty of Pharmacy, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus 
      University in Torun, Poland.
LA  - eng
PT  - Journal Article
DEP - 20180326
PL  - Poland
TA  - Prz Gastroenterol
JT  - Przeglad gastroenterologiczny
JID - 101280380
PMC - PMC5894449
OTO - NOTNLM
OT  - HCV genotype 4
OT  - pegylated interferon
OT  - sustained virological response
EDAT- 2018/04/17 06:00
MHDA- 2018/04/17 06:01
PMCR- 2018/01/01
CRDT- 2018/04/17 06:00
PHST- 2016/12/01 00:00 [received]
PHST- 2017/04/18 00:00 [accepted]
PHST- 2018/04/17 06:00 [entrez]
PHST- 2018/04/17 06:00 [pubmed]
PHST- 2018/04/17 06:01 [medline]
PHST- 2018/01/01 00:00 [pmc-release]
AID - 32318 [pii]
AID - 10.5114/pg.2018.74558 [doi]
PST - ppublish
SO  - Prz Gastroenterol. 2018;13(1):22-29. doi: 10.5114/pg.2018.74558. Epub 2018 Mar 
      26.